- $933.35m
- $1.12bn
- $727.33m
Annual cashflow statement for Neogenomics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -8.35 | -144 | -88 | -78.7 | -108 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | -66.7 | 40.5 | 38.9 | 45.8 | 77.5 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -4.99 | -31.7 | -25.5 | -32.6 | -32.1 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -26.7 | -66 | -1.95 | 7.02 | 5.23 |
| Capital Expenditures | -64.1 | -30.9 | -28.8 | -41.1 | -27 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -568 | 31.4 | 105 | 53.9 | 14.7 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -632 | 0.517 | 76.7 | 12.9 | -12.3 |
| Financing Cash Flow Items | -29.3 | 0 | 0 | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 725 | 11.8 | 4.55 | 4.65 | -200 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 66.2 | -53.6 | 79.3 | 24.5 | -207 |